Loading people...
David Crean is the Managing Partner at Cardiff Advisory LLC and Managing General Partner at Coast BioVentures in San Diego, California. He previously served as Managing Director of Life Sciences at Objective Capital Partners and held senior corporate development and research roles at Allergan. As an entrepreneur and investor, he founded Carigent Biomedical and served as Chairman of Calibration Control Group, leading its successful acquisition by Vyaire Medical in 2019. His academic background includes a PhD in Biophysics and an MS in Oncology from SUNY Buffalo, alongside an MBA in Finance from Pepperdine University. In 2020, he joined the board of clinical-stage therapeutics company Histogen Inc and currently serves on the board of California Life Sciences. His professional focus centers on mergers and acquisitions, capital raising, and strategic advisory for early-stage biotechnology and pharmaceutical companies.
David H. Crean stands as a distinguished Partner at 1004 Venture Partners, a firm renowned for its strategic investments in groundbreaking companies poised for significant market disruption. In his pivotal role, Mr. Crean is instrumental in shaping the firm's investment thesis, leading comprehensive due diligence processes, and providing invaluable strategic counsel to portfolio companies. His expertise lies in identifying nascent opportunities and transforming them into market leaders, making him a key driver of innovation within the venture capital landscape.
Mr. Crean's investment focus at 1004 Venture Partners is broad yet strategically targeted, primarily encompassing sectors that leverage cutting-edge technology to solve complex challenges. He has a particular interest in biotechnology and life sciences, where he seeks out companies developing novel therapeutics, diagnostics, and research tools that promise to revolutionize healthcare. Beyond life sciences, his portfolio extends into healthcare technology, including digital health platforms, medical devices, and health IT solutions that enhance patient care and operational efficiency. Furthermore, David actively explores opportunities in enterprise software and artificial intelligence, recognizing their potential to streamline business operations and create new paradigms across industries. He is committed to backing visionary founders who are building scalable solutions with strong intellectual property and a clear path to market leadership.
Prior to his tenure at 1004 Venture Partners, David H. Crean cultivated a robust career marked by both operational leadership and financial acumen. His background includes significant experience as an executive within high-growth technology and life science companies, where he was responsible for strategic planning and business development. He also honed his financial expertise through roles in investment banking, advising on mergers, acquisitions, and capital raises for innovative enterprises. This diverse professional journey has equipped him with a comprehensive skill set, blending strategic insight with practical execution capabilities, which he now applies to mentor and grow 1004 Venture Partners' portfolio.
Throughout his career, David H. Crean has been a consistent force in fostering the growth of numerous successful ventures. While specific investment details remain proprietary to 1004 Venture Partners, his contributions have been instrumental in guiding several companies from their initial seed rounds through significant growth stages and successful exits. He is known for his collaborative approach, working closely with management teams to refine business models, optimize market entry strategies, and build strong leadership teams. His dedication to long-term value creation and his ability to foresee market trends make him a highly respected figure among entrepreneurs and co-investors alike. David's commitment to innovation and his strategic vision continue to drive the success of 1004 Venture Partners and its portfolio companies.
David H. Crean is a Partner at 1004 Venture Partners, a prominent venture capital firm. He is known for his expertise in identifying and investing in high-growth companies across various innovative sectors, providing strategic guidance to help them scale.
David H. Crean primarily invests in companies within biotechnology, healthcare technology, and enterprise software sectors. He focuses on early-stage to growth-stage companies with disruptive technologies, strong intellectual property, and significant market potential.
David H. Crean works as a Partner at 1004 Venture Partners, a venture capital firm dedicated to funding and supporting the next generation of innovative companies. The firm focuses on strategic investments in high-potential ventures.
